Drugs for Neglected Diseases Initiative
Impact in
-
- Research on Leishmaniasis Studies
- Malaria Research and Control
- Epidemiology top 10%
- Trypanosoma species research and implications
Papers in
- Microbiology 12
-
- Research on Leishmaniasis Studies 191
- Malaria Research and Control 36
- Top scholars
- Eric ChatelainSimon L. CroftJorge AlvarManica BalasegaramJean‐Robert IosetBernard PécoulIsabela RibeiroPiero Olliaro
- Journals
- PLoS neglected tropical diseases (109 papers)Antimicrobial Agents and Chemotherapy (23 papers)Malaria Journal (20 papers)Journal of Medicinal Chemistry (18 papers)Journal of Antimicrobial Chemotherapy (17 papers)
- Partner nations
- SwitzerlandUnited KingdomUnited States
In The Last Decade
Drugs for Neglected Diseases Initiative
635 papers receiving 24.7k citations
Peers
Comparison fields: 5 of 182
- Public Health, Environmental and Occupational Health 9.8k
- Epidemiology 7.8k
- Parasitology 1k
- Microbiology 91
- Applied Microbiology and Biotechnology 237
Countries citing scholars working at Drugs for Neglected Diseases Initiative
This map shows the geographic impact of research produced by authors working at Drugs for Neglected Diseases Initiative. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers produced at Drugs for Neglected Diseases Initiative with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Drugs for Neglected Diseases Initiative more than expected).
Fields of papers published by authors at Drugs for Neglected Diseases Initiative
This network shows the impact of papers affiliated with Drugs for Neglected Diseases Initiative at the time of their publication. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers affiliated with Drugs for Neglected Diseases Initiative at the time of their publication.
About Drugs for Neglected Diseases Initiative
In recent decades, authors affiliated with Drugs for Neglected Diseases Initiative have published 670 papers, which have received a total of 24.7k indexed citations . Scholars at this organization have produced 12 papers in Microbiology, 258 papers in Public Health, Environmental and Occupational Health, 201 papers in Epidemiology, 92 papers in Infectious Diseases and 9 papers in Applied Microbiology and Biotechnology on the topics of Research on Leishmaniasis Studies (191 papers), Trypanosoma species research and implications (185 papers), Malaria Research and Control (36 papers), Pharmaceutical Economics and Policy (35 papers), Parasitic Diseases Research and Treatment (31 papers), Pharmaceutical studies and practices (26 papers), SARS-CoV-2 and COVID-19 Research (17 papers) and HIV/AIDS drug development and treatment (16 papers). Their work is cited by papers focused on Public Health, Environmental and Occupational Health (9.8k citations), Epidemiology (7.8k citations), Parasitology (1k citations), Microbiology (91 citations) and Applied Microbiology and Biotechnology (237 citations). Authors at Drugs for Neglected Diseases Initiative collaborate with scholars in Switzerland, United Kingdom and United States and have published in prestigious journals including PLoS neglected tropical diseases, Antimicrobial Agents and Chemotherapy, Malaria Journal, Journal of Medicinal Chemistry and Journal of Antimicrobial Chemotherapy. Some of Drugs for Neglected Diseases Initiative's most productive authors include Eric Chatelain, Simon L. Croft, Jorge Alvar, Manica Balasegaram, Jean‐Robert Ioset, Bernard Pécoul, Isabela Ribeiro, Piero Olliaro, Thomas P. C. Dorlo and Farrokh Z. Modabber.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.